The elevated risk of telangiectasia associated with the TP53 ProA2 haplotype was found only in patients who did not present with acute toxicity during radiotherapy (OR 2.78, 95% CI: 1.44–5.35) and not in those who experienced acute skin toxicity during radiotherapy (Pheterogeneity=0.06) (Table 3). Here, TP53 is linked to telangiectasis.